Results 151 to 160 of about 7,681 (165)

Maraviroc: The First of a New Class of Antiretroviral Agents

Clinical Infectious Diseases, 2008
Rodger D Macarthur
exaly  

Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects

British Journal of Clinical Pharmacology, 2008
Angus N R Nedderman, Samantha Abel
exaly  

Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers

British Journal of Clinical Pharmacology, 2008
Samantha Abel
exaly  

Drug safety evaluation of maraviroc for the treatment of HIV infection

Expert Opinion on Drug Safety, 2012
Jan-Christian Wasmuth, Jürgen Kurt Rockstroh   +1 more
exaly  

Efficacy and Safety of Maraviroc Versus Efavirenz, Both With Zidovudine/Lamivudine: 96-Week Results From the MERIT Study

HIV Clinical Trials, 2010
Jayvant Heera, James Goodrich, Howard Mayer   +2 more
exaly  

Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir

British Journal of Clinical Pharmacology, 2010
Bharat Damle, Paul Glue
exaly  

Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers

British Journal of Clinical Pharmacology, 2008
Samantha Abel, Elna van der Ryst
exaly  

Preclinical discovery and development of maraviroc for the treatment of HIV

Expert Opinion on Drug Discovery, 2015
Sanja Glisic, Nevena Veljkovic, Marco Radi   +2 more
exaly  

Maraviroc: in vitro assessment of drug–drug interaction potential

British Journal of Clinical Pharmacology, 2008
Maurice Dickins
exaly  

Primary resistance to maraviroc in a large set of R5-V3 viral sequences from HIV-1-infected patients.

Journal of Antimicrobial Chemotherapy, 2010
Eduardo Seclen, Carmen de Mendoza, Antonio Aguilera   +2 more
exaly